HealZen Therapeutics and Shanghai Institute of Materia Medica Announce Clearance of Investigational New Drug（IND）Application For New BTK Degrader HZ-Q1070 for the Treatment of Relapsed or Refractory B-cell Lymphoma
TIME：
Nov 29,2023
Hangzhou, Nov.29,2023 – Hangzhou HealZen Therapeutics and Shanghai Institute of Materia Medica, Chinese Academy of Sciences, announced that Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has cleared the Investigational New Drug（IND）application for new BTK degrader HZ-Q1070, a medicine in development for treat relapsed or refractory B-cell lymphoma (R/R BCM) in China.
Related News
Jan 10,2025
HealZen/SIMM Announce Global License and Strategic Collaboration to Advance BTK Degrader
Jun 19,2024
The innovative drug HZ-H08905 tablets of Hangzhou HealZen Therapeutics Co., Ltd has been approved for a pivotal Phase III clinical trial for the treatment of recurrent or refractory peripheral T-cell lymphoma
Hangzhou HealZen Therapeutics Co., Ltd recently announced that its independently developed Class 1 innovative drug, HZ-H08905 (CK1ε&PI3Kδ dual-target inhibitor), has been officially approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), China, to conduct a pivotal registration Phase III clinical trial for the treatment of recurrent or refractory peripheral T-cell lymphoma (R/R PTCL).
HealZen Therapeutics Co., Ltd.
Telephone: +86-571-86933001
E-mail: info@healzentx.com
Address: 8th Floor, Building 16, Hexiang Science and Technology Center, Qiantang District, Hangzhou City, P.R.China
Copyright © HealZen Therapeutics Co., Ltd. Powered by www.300.cn